Page 26 - Pcr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GHENT, Belgium, June 15, 2023--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discov

According to the fact-finding report, the teenager had been under stress and expressed her desire to discontinue her studies at the institution following the Eid vacation.

Coaches and players from both teams were allegedly involved in an incident.

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Results from a prognostic genomic assay convinced a group of Spanish oncologists to change treatment plans for 56% of 89 patients with HER2-positive (HER2+) early breast cancer.